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Clinical Observations 
Effect of Busui Shengxue Granule (㸹傧⫳㸔乫㉦) on Chronic Aplastic 
Anemia Patients’ Hematopoietic Adhesion Molecule VLA-6/CD49f and  
Its Ligand Laminin 
WANG Jin-huan⥟䞥⦃, SUN Wei-zhengᄭӳℷ, and SUN An-taoᄭኌᓶ
Objective: To observe the effect of Busui Shengxue Granule (㸹傧⫳㸔乫㉦ Herbal granule for replenishing marrow 
to produce blood) on chronic aplastic anemia (CAA) patients’ integrin Į 6 (VLA-6/CD49f) and laminin (Ln).  
Methods: Sixty-five patients were divided intoexperimental group and control group through random number table. 
There were 34 patients, 17 were male and 17 female, aged 2–67, with a medianage of 30.2 ± 8.6, in the experimental 
group, including 17 patients of kidney-yin deficiency and 17 of kidney-yang deficiency, treated by Busui Shengxue 
Granule. There were 31 patients in the control group,16 were male and 15 female, aged 4–65, with a medianage of 31.2 
± 8.0; administered Zaizhang Shengxue Tablet (ݡ䱰⫳㸔⠛Herbal tablet for chronic aplastic anemia). Both groups were 
treated for six months and compared with 10 normal persons after the treatment. Flow cytometry was adopted to detect 
the change in the expression of VLA-6/CD49f, receptor in mononuclear cells of CAA patients and normal persons. 
Enzyme-linked immunosorbent assay was applied to detect the expression of peripheral serum Ln.  
Results: CAA patients’ VLA-6/CD49f was in the state of low expression and Ln in the state of high expression. After 
the treatment, both VLA-6/CD49f and Ln were regulated to some extent and the change in the experimental group was 
better than that of the control group. Compared with the kidney-yin deficiency patients, those indices of kidney-yang 
deficiency patients were easier to correct.  
Conclusion: The VLA-6/CD49f and Ln expressions of CAA patients are abnormal. The treatment with Busui 
Shengxue Granule makes both of them improved. 
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In recent years, British Committee for Standards in 
Haematology defined Aplastic Anemia (AA) as the state 
of low medullary hyperplasia and peripheric 
pancytopenia, excluding marrow infiltration and retinal 
scleroprotein increase. It mainly means the trait acquired 
AA, not referring to the aplastic bone marrow after the 
chemotherapy and radiotherapy. Chronic aplastic anemia 
(CAA), characterized with slow and concealed onset, is a 
chronic disease. With effective treatment, it can be eased, 
however, it can be induced easily too. What’s more, few 
CAA patients may experience clinical deterioration and 
turn to acute aplastic anemia, namely SAA-II, which is a 
critical condition with a poor prognosis. Thus, it is 
significant to make deep studies on this disease. Cell 
adhesion molecules (CAM) are transmembrane 
glycoproteins which exist on the cell surface. The 
interaction between mediating cell and cell or cell and 
extracellular matrix may exert influence on cell’s 
proliferation, differentiation, supersession, transference 
and dynamic interaction between cells. This research 
takes myeloid element, stromal cell and peripheric serum 
in the hematopoietic microenvironment as the main study 
objects, observing the change of cell adhesion molecules’ 
receptors and corresponding ligands. The report is as 
follows.    
METHODS 
Case Selection
Objects: Sixty-five cases in this research were all 
hospitalized patients and outpatients during November 
2004 to April 2007. They were divided into experimental 
group and control group through random number table,
all group peoples sign the informed agreement. Of the 34 
patients in the experimental group, 17 were kidney-yang 
deficiency and 17 kidney-yin deficiency, 17 were male 
and 17 female, aged 2–67, with a medianage of 30.2 ± 
8.6. Of the 31 cases in the control group, 16 were male 
and 15 female, aged 4–65, with a medianage of 31.2 ± 
8.0. There were 10 people in the normal control group, 
all healthy blood donors, 5 were male and 5 female,aged 
12-65,with a medianage of 32.6±7.5.1
Diagnostic Standard: 
1. CAA Diagnostic Standard: All patients were primary 
CAA. Treatment and effect judgment were conducted 
according to Diagnosis and Therapeutic Effect Criterion 
of Hematonosis.1
1) Clinical manifestation: slow onset, slight anemia, 
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infection, and hemorrhage. 
2) Hemogram: hemoglobin decreased slowly. Number of 
reticulocyte, leukocyte, neutrophil and platelet was more 
than that of acute aplastic anemia. 
3) Hemomyelogram: a) Series 3 or 2 decreased. At least 
one part experienced undesirable proliferation. If 
proliferation was good, there would be the increased 
orthochromatic norm oblasts in erythrocytic series and 
obvious decrease of megakaryocytes. b) Non- 
hematopoietic cells and adipocytes in bone marrow 
increased. 
4) Deterioration in clinical symptoms with hemogram 
and hemomyelogram similar to those of acute aplastic 
anemia was called heavy aplastic anemia II. 
2. TCM syndrome differentiation diagnostic standard for 
experimental group: Based on the Guiding Principles of 
Clinical Researches on New Chinese Medicines, the 
experimental group was subdivided into kidney-yang 
deficiency and kidney-yin deficiency. 
1) Kidney-yang Deficiency 
Main symptoms: palpitation, dizziness, pale face and lips, 
general weakness, cold extremities, soreness and 
weakness in waist and knees. Secondary symptoms: 
sexual dysfunction, loose stools, no or slight bleeding, 
pale tongue, deep thready pulse. There were 17 such 
cases in the experimental group. 
2) Kidney-yin Deficiency 
Main symptoms: palpitation, dizziness, pale face and lips, 
general weakness, night sweating, hemorrhage. 
Secondary symptoms: low fever, feverish palms and 
soles, thirst with desire to drink water, dry stools, pale 
tongue or red tip of tongue, thready rapid pulse. There 
were 17 such cases in the experimental group. 
Exclusion: 
Pregnant, breast-feeding women; psychotic patients; 
those with incomplete clinical data; patients with 
insufficient treatment (less than 6 months); those not take 
medicine as required; quitters; those involved in other 
clinical research in recent three months; patients with 
uncontrollable hemorrhage or infections, other hemo- 
pathic or malignant disease.  
Treatment 
All patients stopped taking other CAA medicines for 
more than 2 weeks.  
Busui Shengxue Granule, composed of Shu Di Huang 
(Radix Rehmanniae Praeparata), Shan Yu Rou (Fructus 
Corni), Gou Qi Zi (Fructus Lycii), Yin Yang Huo (Herba 
Epimedii), Ba Ji Tian (Radix Morindae Officinalis), Lu 
Rong (Cornu Cervi Pantotrichum), Ren Shen (Radix 
Ginseng), Huang Qi (Radix Astragali), Dan Shen (Radix 
et Rhizoma Salviae Miltiorrhizae), Ji Xue Teng (Caulis 
Spatholobi), Bai Hua She She Cao (Herba Hedyotis 
Diffusae), and Zhu Ling (Polyporus), etc., prepared by 
the Pharmaceutical Factory of the First Affiliated 
Hospital, Heilongjiang University of Chinese Medicine, 
lot number 19970048, 15 g/bag, each bag containing 25 
g crude medicine, was applied to the experimental group, 
1 bag each time, 3 times daily, mixed with water and 
drunk as tea.  
Zaizhang Shengxue Tablet, composed of Tu Si Zi 
(Semen Cuscutae), Hong Shen (Radix et Rhizoma 
Ginseng Rubra), E Jiao (Colla Corii Asini), Huang Qi 
(Radix Astragali), Dang Gui (Radix Angelicae Sinensis), 
Shu Di Huang (Radix Rehmanniae Praeparata), Zhi He 
Shou Wu (Radix Polygoni Multiflori Praeparata), Yin 
Yang Huo (Herba Epimedii), Huang Jing (Rhizoma 
Polygonati), Lu Rong (Cornu Cervi Pantotrichum), Xian 
He Cao (Herba Agrimoniae), and Gou Qi Zi (Fructus 
Lycii), etc., produced by Liaoyuan Yadong 
Pharmaceutical Factory, Jilin Province, State Food and 
Drug Administration approval number Z22025856, 0.35
g/tablet, was applied to the control group, 5 tablets each 
time, 3 times daily.  
Both groups were treated for 3 months as one course and 
the effect was judged after 2 courses and one year’s 
follow-up. 
Reagents and Instruments 
1. VLA-6/CD49f: PE staining Monoclonal antibody CD49f 
provided by USA BD Pharmingen Company; RCLB 
provided by USA BD Company FACS lysing solution®; 
flow cytometry provided by USA BD Company 
FACSort®; test tube provided by Austria Greiner 
Company Vacuette®; anticoagulant EDTA K2; centrifuge 
provided by Zhengzhou Medical Equipment Plant.   
2. Ln: Ln kit provided by Senxiong Biotechnology 
(Shanghai) Company; centrifuge: Zhengzhou Medical 
Equipment Plant; ELIASA Clinibio 128, Epson USA. 
Test Method
1. Detecting VLA-6/CD49f with Flow cytometry (FCM): 
Before and after treatment, 3 mL bone marrow drawn 
from the posterior or anterior superior iliac spine was put 
into a test tube with EDTA K2 in it. The specimen was 
processed and dyed within 6 hours after collection. The 
100 μL bone marrow with EDTA K2 in it was put into 
each tube, 10 μL CD45 dyed by PerCP was added to 
each tube and then 10 μL McAb was added. The mixture 
should be shaken well and incubated in dark for 20–30 
min in normal roomtemperature. RCLB 1 mL was added. 
Incubation in dark for 10 min in normal room 
temperature was carried out. After centrifugation for 5 
min at 1000 rpm, the supernatant was removed. PBS was 
added for washing 2 times. The volume was expanded to 
400–600 μL at the same time. Getting 10,000 cells per 
tube with flow cytometry. Analysis was done with the 
Cell Quest 3.0 software. 
2. Detecting Ln with ELISA 
1) Preparation of Specimen: Draw 2 mL of venous blood 
from the CAA patients and the donor and put it into the 
test tube without pyrogen and endotoxin. Centrifugate 
for 20 min under the circumstance of 4 ć and 3,500 rpm 
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Take the supernatant and subpackage according to daily 
need. The supernatant should be in cryostorage at -20  ć
for research. Pay attention to removing the hemolysis or 
high blood lipid samples. 
2. Operating Procedure: Take out the ELISA plate and 
add 50 μL standard into each blank micropore in 
accordance with the order; sign the number of the 
samples and add 50 μL sample into the blank micropore; 
add 100 μL enzymelabelling solution to each pore; 
incubate at 37 ć for 60 min; wash by plate cleaning 
instrument for 5 times and stew for 10–20 seconds each 
time; add 50 μL substrate A and B to each pore; incubate 
in dark for 15 min at 37 ć; add 50 μL stop-solution to 
each pore; measure the light absorption value at a 
position of 450 nm; calculate the Ln content. 
Statistical Analysis
Measurement data should be tested by using t test. The 
data should be represented as x f s; inter block 
comparison should apply the pair t test; comparison 
between groups should employ the method of F test to 
do ANOVA; paired comparison is to be done by q test. 
Adopt SPSS 11.0 to analyze the result, take P<0.05 as 
having statistically significant difference.  
RESULTS 
VLA-6/CD49f Expression of Mononuclear Cells of 
Bone Marrow 
The VLA-6/CD49f expression of the Experimental Group 
and Control Group before & after treatment (Table 1) 
Table 1. The VLA-6/CD49f expression of the experimental group and control group before & after treatment ( xfs) 
Group Cases Before treatment After treatment 
Experimental group 34    23.25±5.71**Ÿ  56.56±8.16*ƸƔ
Control group 31   24.32±5.42** 46.49±9.33*Ƹ
Normal group 10 79.67±9.75 ̢
Notes: Compared with the normal group, *P<0.05, **P<0.01;,ƹP>0.05; Compared among the groups, ŸP>0.05.  
From the Table 1, it can be seen that, before the treatment, 
the mononuclear cells’ VLA-6/CD49f expression of the 
experimental group and control group is lower than that 
of the normal group (P<0.01) and there is no significant 
difference between the two groups (P>0.05); after the 
treatment, both of the groups experience restoration and 
there is a great difference between them (P<0.05); 
compared with itself before treatment, there is a great 
difference (P<0.05), however, compared with the normal 
group, there is still great difference. 
The VLA-6/CD49f expression of kidney-yang deficiency 
and kidney-yin deficiency before & after treatment 
(Table 2).  
Table 2. The VLA-6/CD49f expression of kidney-yang deficiency and kidney-yin deficiency before & after treatment  
( xfs)
Group Cases Before treatment After treatment 
Kidney yang deficiency 17  25.30±5.81**Ÿ   61.75±9.23**ƸƸƔ
Kidney yin deficiency 17 21.42±5.65** 49.37±7.43**Ƹ
Normal group 10 79.67±9.75 ̢
Notes: Compared with the normal group, *P<0.05, **P<0.01; Compared with itself before treatment, ᇞP<0.05, ᇞᇞP<0.01, ƹP>0.05;  
Compared among the groups, ƔP<0.05, ƔƔP<0.01, ŸP>0.05.
From Table 2, it can be seen that, before the treatment, 
the mononuclear cells’ VLA-6/CD49f expression of 
kidney-yang deficiency and kidney-yin deficiency has no 
distinctive difference (P>0.05) and is lower than that of 
the normal group (P<0.01); after the treatment, both of 
the groups experience restoration of different degrees, 
compared with before treatment, there is a great 
difference (P<0.05), compared among the groups, there 
is a great difference (P<0.05), compared with the normal 
group, there is still a great difference. 
Ln Expression of Peripheral Serum 
The Ln expression of the experimental group and control 
group before & after treatment (Table 3). 
Table 3. The Ln expression of the experimental group and Control group before & after treatment ( xfs)
Group Cases Before treatment After treatment 
Experimental group 34  38.31±9.73**Ÿ  19.41±5.78ƿƔƔƸƸ
Control group 31 39.44±7.20** 23.72±6.90**ƸƸ
Normal group 10 15.90±5.15 ̢
Notes: Compared with the normal group, *P<0.05, **P<0.01, ƿP>0.05; Compared with itself before treatment, ᇞP<0.05, ᇞᇞP<0.01,  
ƹP>0.05; Compared among the groups, ƔP<0.05, ƔƔP<0.01, ŸP>0.05.
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It can be seen that the Ln expression between the 
experimental group and control group before the 
treatment has no distinctive difference (P>0.05) and is 
higher than that of the normal group, and there is a 
significant difference compared with the normal group 
(P<0.01); after the treatment, the Experimental group 
and Control group have a great difference (P<0.01), and 
there is no distinctive difference between the 
experimental group and normal group (P>0.05), but there 
is still a distinctive difference between the control group 
and normal group (P<0.01). Refer to the inter block 
comparison, both of the two groups have a great 
difference (P<0.01).  
The Ln expression of kidney-yang deficiency and 
kidney-yin deficiency before & after treatment (Table 4)  
Table 4. The Ln expression of kidney-yang deficiency and kidney-yin deficiency before & after treatment ( xfs)
Group Cases Before treatment        After treatment 
Kidney-yang deficiency 17   36.04±9.41**Ÿ   17.14±4.45ƿƔƸƸ
Kidney-yin deficiency 17 40.57±9.79** 21.68±6.18*ƸƸ
Normal group 10 15.90±5.15 ̢
It can be seen that in the between-group comparison the 
Ln expression of the kidney-yang deficiency group and 
kidney-yin deficiency group before treatment has no 
significant difference (P>0.05) and is higher than that of 
the normal group, and there is a significant difference 
compared with the normal group (P<0.01); after the 
treatment, the kidney-yang deficiency group and 
kidney-yin deficiency group have a great difference
(P<0.05), and there is no significant difference between 
the kidney-yang deficiency group and normal group 
(P>0.05), but there is still a significant difference 
between the kidney-yin deficiency group and normal 
group (P<0.05). Refer to the inter block comparison, 
both of the two groups have a great difference (P<0.01).  
DISCUSSION 
Busui Shengxue Granule is the product of the seminar’s 
long-term exploration. specific to its pathological change 
that CAA is closely related to kidney deficiency, the 
seminar summarizes years of clinical experience, 
consults the modern pharmacology, takes tonifying the 
kidney as the treating principle, uses Chinese medicines 
tonifying the kidney as well as those promoting blood 
circulation by removing blood stasis and clearing away 
heat and toxic material, successfully accomplishes the 
production of Busui Shengxue Granule.  
Busui Shengxue Granule is effective in reinforcing the 
kidney yang, producing marrow, and nourishing the 
blood. As for the components, Shu Di Huang can tonify 
the kidney and replenish essence, nourish yin and blood; 
Ba Ji Tian is effective in tonifying the kidneying and 
supporting yang, nourishing marrow and blood; Hong 
Shen has the effect of reinforcing vital energy; Ji Xue 
Teng can promote blood circulation by removing blood 
stasis, which is in accordance with the old saying 
“pathogen usually intruding into collateral in protracted 
disease”. The Chinese herbalist doctors hold that the key 
cause of CAA is kidney deficiency and the treatment 
should take tonifying the kidney as the principle. 
However, based on the theory of “renal yin and renal 
yang” and “interdependence between yin and yang”, the 
prescription should contain not only medicines 
nourishing yang but also those nourishing yin. This can 
make yin and yang equilibrated, so consequently 
promote hemogenesis. Tonifying the kidney can ease the 
symptom of kidney deficiency. What’s more, it can 
improve and adjust the balance and coordination of 
neuro-endocrine-immune network fundamentally, and 
then promote the ability of “hematopoiesis”.          
Generally, CAM molecule can be divided into three parts: 
extracellular part is the N-terminal, which is generally 
big, with a sugar chain and responsible for distinguishing 
and combining with its ligand; transmembrane part is 
mostly single pass; cytoplasmic part is generally small 
and can link with the skeleton component under the 
plasmalemma to conduct signals, or has protein tyrosine 
kinase activity and phosphorylation sites.   
Action mechanism of CAM has three modes: mutual 
recognition and binding between homophilic cell 
adhesion molecules on the surfaces of two flanking cells 
(homophilic adhesion); mutual recognition and binding 
between heterophilic cell adhesion molecules on the 
surfaces of two flanking cells (heterophilic adhesion); 
mutual recognition and binding between homophilic cell 
adhesion molecules on the surfaces of two flanking cells 
through the extracellular linkers. 
With the development of biology and immunology, it is 
found that adhesion molecule is related to anything 
happened in our bodies. Consequently, adhesion 
molecule has been a research focus.   
In the preliminary study, we took the myeloid element 
and stroma cell in the hemopoietic microenvironment as 
our main study objects and try to observe the change of 
adhesion molecules and hematopoietic regulatory factors 
on its surface. The research result shows that adhesion 
behavior of CAA’s hematopoietic stem cells, 
hemopoietic progenitors, as well as the adhesion 
molecules and hematopoietic regulatory factors are 
abnormal.2-4 It is also found that, in the hemopoietic 
microenvironment, besides the hematopoietic cells and 
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stromal cells, the abnormality of adhesion molecules also 
happen to other cells, such as T, B lymphocyte, and 
granular leukocytes. The abnormality of these cells’ 
adhesion molecules also has an important influence on 
the nosogenesis of aplastic anemia immunity.    
The existing documents and research results show that 
the compound formulas, which take kidney tonifying and 
hemogenesis as the core, could take effect in CAA 
treatment from different aspects, such as regulating the 
immunity, promoting the hematopoietic cell proliferation, 
and improving the hemopoietic microenvironment, etc. 
Then, is there a mutual mechanism for the multi-target 
effect — which affects the expression of the adhesion 
molecule, sequentially exerts influence on the immune- 
ologic mechanism, hematopoietic microenvironment 
damage mechanism, and even the apoptosis mechanism? 
This needs further study.  
Pathologic and Physiological Properties of VLA-6/ 
CD49f  
VLA-6/CD49f has A and B, two allotypes. The former 
one is expressed at lung, liver, spleen and cervical, and 
the latter is expressed at brain, ovary and kidney. Both of 
them are expressed at thymus cells, T cells, monocytes, 
and platelets. The VLA-6/CD49f expression of activated 
T cells and memory T cell is increased. VLA-6/CD49f’s 
ligand is Ln. Ln, combined with VLA-6/CD49f on the T 
cell, provides the costimulatory signal for T cell’s 
activation and proliferation. Ln, combined with VLA- 
6/CD49f, also participates in fetation. Protein kinase C 
(PKC) activator PMA could stimulate CD49f subunit to 
be phosphorylated.    
It is clear now, hematopoietic stem / progenitor cell 
homing is a multi-step process, in which its traversing of 
endothelium is dependent on some homing-related 
molecules on the surfaces of hematopoietic stem / 
progenitor cells, especially the expression level of two 
members of ȕ1 integrin family — CD49e and CD49f.5
Effect of Reinforcing Kidney Medicines on VLA-6/ 
CD49f
In this research, the authors found that the VLA-6/CD49f
expression level of bone marrow mononuclear cell of 
CAA patients was significantly lower than that of the 
normal group (P<0.01). After the treatment with Busui 
Shengxue Granule, the expression recovered to some 
extent, but still didn’t reach the normal level (P<0.05). 
The healing effect on treatment group was better than on 
control group. 
And there was no great difference between the kidney- 
yang deficiency type and kidney-yin deficiency type
(P<0.05). The results suggest that: 1) the expression of 
adhesion molecule VLA-6/CD49f of CAA patient’s bone 
marrow mononuclear cell is in a low state; 2) Busui 
Shengxue Granule could raise the expression level of 
VLA-6/CD49f and the increase is larger than that of the 
control group; 3) Busui Shengxue Granule’s effect on 
Kidney-yang deficiency patients is better than on 
Kidney-yin deficiency patients (P<0.05). 4) After the 
treatment with Busui Shengxue Granule, the expression 
level of VLA-6/CD49f is still different from that of the 
normal group. This may be caused by small dosage and 
short medication time. Thus, we speculate that the 
decline of VLA-6/CD49f expression lowers the ability of 
hematopoietic stem / progenitor cell migration and 
homing, and consequently causes CAA. 
Pathologic and Physiological Properties of Ln 
Ln, one of the main components of cell basement 
membrane, belongs to the non-collagenous glycoprotein 
of extracellular matrix and is distributed in the stratum 
lucidum of basilar membrane. Ln, Č-C, and chondroitin 
sulfate keep the completeness of basilar membrane.6,7
Laminin is a heterotrimer composed of three polypeptide 
chains, Į, ȕ, Ȗ.8 Till now, five Į chains (Į1–Į5), three ȕ
chains (ȕ1–ȕ3) and two Ȗ chains (Ȗ1, Ȗ2) have been 
proved. By spin projection and negative stain electron 
micrograph, it is shown that laminin is a asymmetric 
cross, composed of a long arm and three similar short 
arms. Generally, cell doesn’t combine with collagen type 
IV or proteoglycan directly, but anchors on the 
basilemma through laminin. There are at least two 
different receptor binding sites in laminin: the combining 
site for collagen type IV and combining with the integrin 
on the cytomembrane through its own R-G-D sequence.
Early in 1980, Terranova found that Ln had the effect of 
enhancing intercellular adhesion. With the deepening 
study on laminin, people found its biological function 
was extremely wide.9 It has been proved that, through the 
interaction with cells, laminin could control directly or 
indirectly activity of cells, such as adhesion or transfer, 
differentiation and polarization, proliferation or apoptosis 
and gene expression. 
Ln is the ligand of VLA-6/CD49f, the subfamily adhesion 
molecule of integrin VLA. As the transmembrane 
glycoprotein receptor, the extracellular domain of VLA-6 
/CD49f participates in the combination with extracellular 
matrix ligand and the intracellular domain, linking with 
intracellular signaling systems and skeleton components, 
mediates the outward transmit of intracellular signal and 
inward transmit of extracellular signal.10  
In some diseases, Laminin content in the local tissues or 
body fluid may have some corresponding changes.11
Some research shows that many tumor patients’ serum 
Ln rises significantly.12 ZHOU, et al,13 adopting the 
radioimmunoassay, assayed the serum Ln of 63 
lymphoma patients and 28 normal persons and 
consequently found that the Ln level decreased with the 
ease of disease, rose with the relapse. This could reflect 
the change of disease state to some extent. 
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It is found in some researches that myclodysplastic 
syndrome and acute and chronic leukemia have the 
condition of Ln rising abnormally and won’t be 
influenced by the healing effect of chemo-treatment and 
chronic leukemia’s state.14 Some other researches show 
that laminin’s antisense RNA could influence the 
expression of E-cadherin, the signaling molecule in
Transforming Growth Factor (TGF)-ȕ1, and Focal 
Adhesion Kinase (FAK).15  
WANG, et al,16 adopting the method of suppression 
substractive hybridization, dissociate the splenic cells’ 
differentially expressed genes of CAA mice which are 
treated with Jianzhong Decoction (ᓎЁ∸) of fourteen 
ingredients and the control mice. The results show that 
the CAA mice’s gene expression of laminin receptor 
reduce and Jianzhong Decoction of fourteen ingredients 
could raise its expression, which may promote the signal 
transmission between cells.17  
Effect of Reinforcing-kidney Herbal Medicines on Ln
In this research, the authors found that CAA patients’ 
peripheral serum Ln expression was apparently higher 
than the normal group’s. Compared with the normal 
group, the difference was significant (P<0.01). After the 
treatment, the Ln expression of most patients in the 
experimental group recovered to the normal level and 
there was no great difference between these two groups 
(P>0.05). The marked difference between the control 
group and the normal group still existed (P<0.01). There 
was a significant difference between the experimental 
group and the control group (P<0.01). The same situation 
appeared between the healing effect of the Kidney-yang 
deficiency and Kidney-yin deficiency patients (P<0.05). 
The results suggest that 1) CAA patient’s peripheral 
serum Ln expression is higher than normal person’s; 2) 
Busui Shengxue Granule could lower the peripheral 
serum Ln expression to normal, which is better than the 
control group; 3) Busui Shengxue Granule’s effect on the 
Kidney-yang deficiency patients’ peripheral serum Ln 
expression is different from its effect on the Kidney-yin 
deficiency patients. 
In the very research, the peripheral blood’s Ln, treated by 
the Chinese medicine, gets close to the normal level. If 
this result can get a further validation, it will provide our 
researching for the best effect target of CAA treatment 
with Chinese medicine with scientific basis. Moreover, 
different types of CAA patients who use the reinforcing 
kidney medicines have difference in their Ln. The Ln 
expression of Kidney-yang deficiency patients reached 
the level of the normal control group, however, 
compared with the normal control group, the Ln 
expression of Kidney-yin deficiency patients still has a 
difference. For this reason, it seems Ln can be the 
objective material basis of different clinical effect for 
different patients.  
The authors’ research shows that, as Ln’s receptor, 
VLA-6/CD49 expression of CAA patient is declining. 
From this, it can be speculated that VLA-6/CD49’s 
reduction causes the increase of free Ln in the peripheral 
blood, which won’t combine with CD49f. Ln expression 
of peripheral blood can reflect the state of aplastic 
anemia. After the treatment with Chinese medicine, 
patient’s condition is improved and Ln expression gets 
close to normal. From another perspective, the Chinese 
medicine’s regulation on Ln indirectly exerts influence 
on the expression of TGF-ȕ1, the negative hematopoietic 
regulator. It lowers TGF-ȕ1’s expression and relieves 
TGF-ȕ1’s repression on hematopoiesis. 
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